In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Fin-ished, for now: Aqua Cultured Foods shutters as funding dries up
In Chicago, a fermentation startup converting cellulose into seafood alternatives has wound down operations after failing to raise funds necessary to reach commercialization.
Established...
Mercedes unveils vegan-interior SUV at CES
In Nevada, Mercedes-Benz has showcased a new, vegan-interior GLC electronic SUV at the recent CES technology trade show in Las Vegas.
Vegan materials were...
Futerro files permits for French PLA site
In France, biobased chemicals maker Futerro has requested the relevant permits for its planned lactic acid and polylactic acid plant in France.
The plant, which...